Macrocyclic polyphenol compound, preparation method thereof and application of macrocyclic polyphenol compound in preparation of medicine for treating cholestasis type liver injury
By isolating macrocyclic polyphenol compounds from 黄花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花花� Serum aminotransferase levels and improve liver damage.
Patent Information
- Application Number
- CN202411190223.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
The existing cholestatic liver injury treatment drugs have not been effectively targeted at cholestatic liver injury, and there is insufficient research on the structure of macrocyclic polyphenol compounds in the extract of 黑花花花花花花花花花花花花花花花花花花花花花花花花花花�
By isolating and purifying macrocyclic polyphenol compounds from 黄花花花 extract, and using macroporous resin column chromatography gradient elution, dextran gel isotropy and ODS reverse column chromatography to prepare therapeutic bile with treatment Compounds of stagnant hepatic injury and are used as dual agonists for treatment of FXR and SIRT1.
The compound significantly reduces the serum aminotransferase level in mice, improves the degree of liver damage, and has the effect of protecting liver and promoting gallbladder, confirming its effectiveness in the treatment of cholestatic liver injury.
Smart Images

Figure CN119080851A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a macrocyclic polyphenol compound, a preparation method thereof, and use thereof in preparing a cholestatic liver injury drug. Background Art
[0002] Cholestasis refers to bile flow disorder caused by diseases of hepatocytes, intrahepatic bile ducts or extrahepatic biliary system. According to the location of occurrence, it is divided into extrahepatic cholestasis and intrahepatic cholestasis. Extrahepatic cholestasis is mostly caused by abnormal anatomical structure of the bile duct, such as congenital biliary atresia, mechanical obstruction (such as stones, tumors) of the bile duct, etc., and physiological function can often be restored through surgery. The causes of intrahepatic cholestasis are diverse, such as congenital bile secretion disorders of hepatocytes and (or) bile duct epithelial cells, immune-mediated fibrocholangitis and drug-induced liver damage. Cholestatic liver disease is a disease caused by obstruction of bile formation and (or) circulation process, bile cannot be secreted normally into the duodenum, resulting in the accumulation of toxic bile and bacteria, causing liver damage, manifested as destruction of hepatocyte integrity, liver fibrosis, cirrhosis and even increased risk of cancer. Cholestatic liver injury is caused by abnormal synthesis, secretion and excretion of bile in hepatocytes or bile capillaries, obstruction of intrahepatic or extrahepatic bile ducts, and induction of persistent cholestasis.
[0003] The nuclear receptor farnesoid X receptor (FXR) is a key regulator of intracellular bile acid receptors and bile acid homeostasis, playing an important role in bile acid, glucose and lipid homeostasis. FXR agonists can increase the transcription of bile salt export pumps to promote intrahepatic bile acid excretion, reduce hepatic bile acid uptake, inhibit the expression of cytochrome 7A1 (CYPA1), the rate-limiting enzyme for bile acid synthesis, and thus reduce excessive bile acid accumulation in the liver. Common FXR agonist drugs currently include obeticholic acid, etc. Silent information regulator (SIRT1) is an NAD-dependent class III histone deacetylase that plays an important role in bile acid metabolism and inflammatory response by regulating deacetylation. SIRT1 can act on FXR through HNF1α, promote the expression of BSEP and SHP, and regulate the synthesis and transport of bile acids. Therefore, SIRT1 is a potential target for regulating bile acid metabolism. At present, drugs that have SIRT1 agonist effects and can improve liver damage include tripterygium wilfordii and 18β-glycyrrhetinic acid.
[0004] Compared with Western medicine, Chinese medicine has the characteristics of multiple targets, multiple pathways, high efficiency and low toxicity, and has good clinical prospects for the development of FXR and SIRT1 dual agonists for the treatment of cholestatic liver disease. The Chinese medicine Penthorumchinense, also known as Chegencai, Shuizelan, Shanzhuzhu, etc., has the effects of promoting blood circulation, removing blood stasis and dampness, and promoting blood circulation and dispersing blood stasis, etc. The chemical components of Penthorumchinense are mainly gallic acid, quercetin, quercetin-3-rhamnoside, and quercetin-7-O-β-D-glucoside.
[0005] There are relevant reports on the pharmacological activity of Herba Chrysanthemi in preventing and treating hepatitis and protecting the liver. For example, patent CN 105125601B discloses an extract of Herba Chrysanthemi and its preparation method and use, and specifically discloses the use of Herba Chrysanthemi extract in the preparation of drugs for preventing and / or treating liver ischemia-reperfusion liver injury and chemical liver injury. Patent CN105193833B discloses the use of Herba Aspergids in preparing liver protection drugs, and specifically discloses the use of chalcone dihydrochalcone-7-O-[3"-O-galloyl-4",6"-hexahydroxybiphenyldicarboxylic acid]-β-D-glucoside in preparing liver protection drugs, which can prevent and treat liver damage and have a definite therapeutic effect on liver ischemia-reperfusion injury and chronic liver damage. Patent CN 108478610A discloses a Herba Aspergids extract and its application, which proves through in vivo and in vitro experiments that the extract can prevent and treat chronic alcoholic liver disease, prevent or treat liver oxidative stress or lipid accumulation. However, the Herba Aspergids extracts disclosed in the above documents are not for the treatment of cholestatic liver damage, and the structure of the new macrocyclic polyphenol compounds in the Herba Aspergids extracts has not been studied in depth. Therefore, it is urgent to further study the composition or structure of the macrocyclic polyphenol compounds in the Herba Aspergids extracts and their therapeutic effects on cholestatic liver damage. Summary of the invention
[0006] Based on the above problems, the present invention provides a macrocyclic polyphenol compound and a preparation method thereof and use thereof in preparing a drug for cholestatic liver injury. After in-depth research, the inventors found that the macrocyclic polyphenol compound extracted from the herb has the effect of treating cholestatic liver injury, and based on this, it is expected to develop a new drug for anti-cholestatic liver injury.
[0007] The present invention is achieved through the following technical solutions:
[0008] A macrocyclic polyphenol compound comprising at least one of the following chemical structural formulas:
[0009]
[0010]
[0011] The above-mentioned compound 2 is prepared by the following method:
[0012] The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract;
[0013] The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4;
[0014] Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4;
[0015] Fr.4.4 was used as a sample and wet loading was performed for ODS column chromatography. Compound 2 was obtained after purification by semi-preparative liquid chromatography.
[0016] The above-mentioned compound 3 is prepared by the following method:
[0017] The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract;
[0018] The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4;
[0019] Fr.3 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.3.1 to Fr.3.3;
[0020] Fr.3.3 was used as a sample and wet loading was performed for ODS column chromatography. Compound 3 was obtained after purification by semi-preparative liquid chromatography.
[0021] The above-mentioned compound 4 is prepared by the following method:
[0022] The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract;
[0023] The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4;
[0024] Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4;
[0025] Fr.4.2 was used as a sample and wet loading was performed for ODS column chromatography. Compound 4 was obtained after purification by semi-preparative liquid chromatography.
[0026] The above-mentioned compound 5 is prepared by the following method:
[0027] The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract;
[0028] The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4;
[0029] Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4;
[0030] Fr.4.3 was used as a sample and wet loading was performed on an ODS column chromatography (30% acetonitrile as the mobile phase). Compound 5 was obtained after purification by semi-preparative liquid chromatography.
[0031] As a preferred technical solution of the present invention, when preparing compounds 2 to 5, the concentrated ethanol extract of the herb is subjected to gradient elution by macroporous resin column chromatography at least twice, with a diameter-to-height ratio of 1:4, 1BV=1.3L, and eluted with 9 to 11BV of 25% ethanol, 50% ethanol, and 95% ethanol in sequence, and the eluate is collected and concentrated under reduced pressure to obtain a 50% ethanol extract, and the 50% ethanol extract is isocratically eluted with methanol-swollen polysaccharide gel LH-20;
[0032] and / or, using Fr.3.3 as sample and wet loading, and performing ODS column chromatography with 30% acetonitrile as the mobile phase;
[0033] and / or, using Fr.4 as sample and dry loading, and performing ODS reverse phase column chromatography with 35% acetonitrile as mobile phase;
[0034] and / or, using Fr.4.2 as sample and wet loading, and performing ODS column chromatography with 33% acetonitrile as the mobile phase;
[0035] and / or, using Fr.4.3 as sample and wet loading, and using 30% acetonitrile as mobile phase for ODS column chromatography;
[0036] And / or, using Fr.4.4 as sample and wet loading method, when performing ODS column chromatography, use 20% acetonitrile as mobile phase.
[0037] A use of a macrocyclic polyphenol compound in the preparation of a cholestatic liver injury drug, wherein the macrocyclic polyphenol compound is at least one of the compounds of the following structural formulas:
[0038]
[0039] Preferably, the drug is a pharmaceutical composition consisting of a macrocyclic polyphenol compound as an active ingredient and pharmaceutical excipients.
[0040] Preferably, the pharmaceutical composition comprises tablets, capsules, granules, powders or pills.
[0041] Compared with the prior art, the present invention has the following beneficial effects:
[0042] The present invention discovers for the first time that macrocyclic polyphenol compounds 1 to 5 can be used as active ingredients for the treatment of cholestatic liver injury. The present invention experimentally studies and confirms that macrocyclic polyphenol compounds can significantly reduce serum transaminase levels and improve the degree of liver damage in mice induced by bile duct ligation, and have the effect of protecting the liver and promoting bile secretion. The present invention also confirms that macrocyclic polyphenol compounds can be used as FXR and SIRT1 dual agonists for the treatment of cholestatic liver injury by detecting the expression levels of FXR and SIRT1 in mouse liver tissue combined with molecular docking experiments, and is expected to develop new drugs against cholestatic injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 to Figure 4 These are the measured values of ALT, AST, ALP, and TBIL in the serum of rats in each experimental group;
[0044] Among them, N represents the normal group; BDL represents the model group; L represents the low-dose PGHG group; H represents the high-dose PGHG group; U represents the positive drug group;
[0045] Figure 5 HE staining results of each experimental group;
[0046] Among them, ×50 means the image is enlarged 50 times, and ×100 means the image is enlarged 50 times.
[0047] Figure 6 Western blot images of each experimental group;
[0048] Figure 7 The protein-ligand interaction diagrams were generated for the visualization analysis of compounds 1-5 using Pymol software.
[0049] A: Docking conformations of compounds 1-5 and FXR; B: Docking conformations of compounds 1-5 and SIRT1. DETAILED DESCRIPTION
[0050] The present invention is described in detail below with reference to specific embodiments.
[0051] [Preparation of Compounds 1 to 5]
[0052] The commercially available Herba Chrysanthemi Indici was crushed and sieved, and extracted twice by 80% ethanol hot reflux, each extraction time was 2 hours, and 80% ethanol V / W in a volume 8 times the weight of the original herbal material was added each time, and the extracts were combined to obtain a 80% ethanol extract of Herba Chrysanthemi Indici.
[0053] The 80% ethanol extract of the herb is concentrated to a 30% ethanol solution. The present invention takes the above 30% herb ethanol solution (50L), and the liquid is eluted twice by macroporous resin column chromatography gradient elution (diameter-height ratio 1:4, 1BV=1.3L), and 10BV of 25% ethanol, 50% ethanol, and 95% ethanol are used for elution in sequence, and the eluate is collected and concentrated under reduced pressure to obtain 70g of 50% ethanol extract. The compounds described in this patent are all in the 50% ethanol part.
[0054] The 50% ethanol fraction was isocratically eluted with dextran gel LH-20 swollen with methanol, and the molecular sieving effect of dextran gel was used to obtain fractions Fr.1 (11 g), fraction Fr.2 (1.4 g), fraction Fr.3 (3.2 g), and fraction Fr.4 (13.5 g). Fr.3 was used as a sample and dry loading was performed on an ODS reverse column chromatography (30% acetonitrile as the mobile phase) to obtain fractions Fr.3.1, Fr.3.2, and Fr.3.3.
[0055] Fr.3.3 was used as a sample and wet loading was performed for ODS column chromatography (30% acetonitrile as mobile phase). After purification by semi-preparative liquid chromatography, compound 3, Uvangoletin-7-O-[4",6"-hexahydroxybiphenyldicarboxylate]-β-D-glucoside, was obtained.
[0056] Fr.4 was used as the sample and dry loading was adopted for ODS reverse column chromatography (35% acetonitrile as the mobile phase) to obtain fractions Fr.4.1, Fr.4.2, Fr.4.3, and Fr.4.4.
[0057] Fr.4.1 was used as a sample and purified by semi-preparative liquid chromatography to obtain compound 1, pyralidin-7-O-[3"-O-galloyl-4",6"-hexahydroxybiphenyl dicarboxylate]-β-D-glucoside (PGHG).
[0058] Fr.4.2 was used as a sample and wet loading was performed for ODS column chromatography (33% acetonitrile as the mobile phase). After purification by semi-preparative liquid chromatography, compound 4, Uvangoletin-7-O-[3"-O-galloyl-4",6"-hexahydroxybiphenyldicarboxylate]-β-D-glucoside was obtained.
[0059] Fr.4.3 was used as the sample and wet loading was performed on ODS column chromatography (30% acetonitrile as the mobile phase). After purification by semi-preparative liquid chromatography, compound 5, pyrocatechol 7-O-{4”,6”-[7”',7””-(3”',3””,4”',4””-tetrahydroxydibenzofurandicarboxyl)]}-β-D-glucoside was obtained.
[0060] Fr.4.4 was used as the sample and wet loading was performed on ODS column chromatography (20% acetonitrile as the mobile phase). After purification by semi-preparative liquid chromatography, compound 2, galangin-7-O-[3"-O-galloyl-4",6"-hexahydroxybiphenyldicarboxylate]-β-D-glucoside (AGHG) was obtained.
[0061] Among them, the NMR data of compounds 2 to 5 are as follows:
[0062] Compound 2: brown powder (methanol), ESI-MS: m / z 885.1533 [MH] - (calcd.for C 43 H 33 O 21 ,885.152). 1H-NMR(400MHz,DMSO-d6)δppm:5.60(1H,m,H-2),3.13(1H,m,H-3),2.69(1H,m,H-3),6.31(1H,t,J=2.5 2Hz,H-6),6.43(1H,t,J=2.15Hz,H-8),3.82(3H,s,H-11),7.54(2H,m,H-2',6'),7.42(3H,m,H-3',4',5 '),5.39(1H,d,J=7.68Hz,H-1”),3.68(1H,t,J=8.4Hz,H-2”),5.33(1H,t,J=9.6Hz,H-3”),4.82(1H,t,J =10Hz,H-3”),5.08(1H,m,H-6”),3.79(1H,m,H-6”),6.90(2H,s,H-3”’,7”’),6.37(1H,s,H-3””),6.25( 1H,s,H-3""'); 13C-NMR (CD3OD, 100MHz) δppm: 78.9 (C-4, 1', 2', 6'), 45.1 (C-4), 94.75 (C-7, 8, 10), 96. 10(C-4,6,9,10),56.50(C-5),127.18(C-2,4'),129.02(C-1',2',6'),99.70(C-7),71.94(C-1”,3”),7 4.65(C-2”,4”,1”’),70.10(C-3”,5”,6”,1””),71.17(C-1”,3”,4”),62.72(C-5”,1””’),109.43(C-2”’ ,3"',4"',5"',6"',7"'),106.09(C-1"",4"",5"",6"",7""),105.78(C-1""',4""',5""',6""',7""').
[0063] Compound 3: white powder (methanol), ESI-MS: m / z 735.1566 [MH] - (calcd.for C 36 H 32 O 17 ,735.1567). 1H NMR(600MHz,CD3OD)δppm:3.33(2H,m,H-1),2.97(2H,t,J=8.02Hz,H-2),6.25(1H,s,H-6),6.25(1H ,s,H-8),3.90(3H,s,H-10),7.27(4H,m,H-2',3',5',6'),7.18(1H,m,H-4'),5.11(1H,d,J=7.70Hz, H-1”),3.61(1H,m,H-2”),3.74(1H,t,J=9.30Hz,H-3”),4.88(1H,m,H-4”),4.14(1H,m,H-5”),5.30 (1H,dd,J=6.42Hz,J=13.36Hz,H-6”),3.85(1H,d,J=13.11Hz,H-6”),6.58(1H,s,H-3”’),6.71(1H,s H-3””); 13 C NMR(150MHz,CD3OD)δppm:45.85(C-2,3,1'),30.43(C-1,3,1',2',6'),96.11(C-4,5,6,7,8),91.77( C-4,6,7,8,9),55.02(C-9,10),128.04(C-2,2',3',4',5',6'),125.57(C-2',3',4',5',6”),100.06( C-7,1”),73.97(C-1”,2”,3”),74.27(C-2”,3”,4”),71.67(C-3”,4”,5”,1””),71.74(C-4",5",6"),6 2.87(C-5",6",1""),107.15(C-1"',3"',4"',5"',6"',7"'),106.84(C-1"",3"",4"",5"",6"",7"").
[0064] Compound 4: white powder (methanol), ESI-MS: m / z 887.1722 [MH]-(calcd.for C 43 H 36 O 21 ,887.1676). 1H NMR (600MHz, CD3OD) δppm: 2.98 (2H, t, J = 7.93 Hz, H-1), 3.35 (2H, m, H-2), 6.29 (1H, s, H-6), 6.27 (1H, s, H-8), 3.91(3H,s,H-10),7.26(4H,m,H-2',3',5',6'),7.18(1H,m,H-4'),5.28(1H,d,J=7.62Hz,H-1”),3.88(1H,m ,H-2”),5.47(1H,t,J=9.64Hz,H-3”),5.11(1H,t,J=9.64Hz,H-4”),4.36(1H,m,H-5”),5.38(1H,dd,J=6.50H z,J=13.36Hz,H-6”),3.88(1H,m,H-6”),6.61(1H,s,H-3”’),6.49(1H,s,H-3””),7.04(2H,s,H-3””’,7””’); 13 C NMR(150MHz,CD3OD)δppm:30.43(C-2,3,1'),45.85(C-1,3,1',2',6'),96.24(C-4,5,6,7,8),91.75( C-4,6,7,8,9),55.05(C-9,10),128.04(C-2,2',3',4',5',6'),125.58(C-2',3',4',5',6”),100.04( C-7,1”),72.09(C-1”,2”,3”),74.51(C-2”,3”,4”),69.95(C-3”,4”,5”,1””),71.50(C-4",5",6"),62 .53(C-5",6",1"')',107.09(C-1"',3"',4"',5"',6"',7"'),106.78(C-1"",3"",4"",5"",6"",7"").
[0065] Compound 5: white powder (methanol), ESI-MS: m / z 701.1156 [MH]-(calcd.for C 35 H 26 O 16 ,701.1148). 1H NMR(600MHz,CD3OD)δppm:5.43(1H,t,9.91,H-2),3.09(1H,m,H-3),2.75(1H,t,J=14.79Hz,H-3 ),6.19(1H,s,H-6),6.22(1H,s,H-8),7.45(2H,m,H-2',6'),7.36(2H,m,H-3',5'),7.36(1H,m, H-4'),5.10(1H,t,J=7.70Hz,H-1”),3.63(1H,s,H-2”),3.82(1H,s,H-3”),5.02(1H,m,H-4”),3 .98(1H,m,H-5”),4.79(1H,m,H-6”),4.05(1H,m,H-6”),7.10(1H,s,H-3”’),7.24(1H,s,H-3””); 13 C NMR(150MHz,CD3OD)δppm:79.21(C-2,4,1',3',5'),42.71(C-3,4,1'),96.67(C-5,6,7,8,10),95.30 (C-6,7,8,9,10),126.02(C-2,2',3',4',5',6'),128.34(C-1',3',4',5'),126.02(C-2',3',4',5', 6'),99.36(C-1”,7),73.27(C-1”,3”),72.99(C-2”,4”),75.17(C-3”,5”,1””),69.62(C-4”,6”),66. 22(C-5”,6”,1”’),110.71(C-1”’,3”’,4”’,5”’,6”’,-7”’),114.96(C-1””,3””,4””,5””,6””,7””).
[0066] The chemical structures of compounds 1 to 5 are as follows:
[0067]
[0068]
Molecular docking simulation experiment
[0069] The following is based on molecular docking experiments to observe the effects of macrocyclic polyphenol compounds from Herba Glehniae on SIRT1 and FXR.
[0070] Experimental methods:
[0071] The monomer compound 1-5 obtained above was selected as the ligand compound, and the result was imported into chemdraw3D20.0 software for energy minimization and saved in .mol2 format, and then the parameters were modified by Autodock tools 1.5.7 software, and finally the file was saved in .pdbqt format.
[0072] Preparation of receptor protein:
[0073] The protein numbers of FXR and SIRT1 were searched in the PDB (https: / / www.rcsb.org / ) online database, and the appropriate protein crystal structure was selected and downloaded from the PDB format file. The receptor protein was edited using pymol software, and the water molecules and residues were removed from the protein. The protein was then imported into autodock tools 1.5.7 software for hydrogenation and energy addition, and finally saved in .pdbqt format.
[0074] Molecular docking:
[0075] In the AutoDock Tool 1.5.7 software, the compound .pdbqt format was selected as the ligand molecule, and the protein .pdbqt format was selected as the receptor protein. The grid box size was set to just cover the receptor protein, and the grid box parameter information was saved in the .gpf format. The genetic algorithm was selected, and the number of dockings was selected to be 50. After adjusting the final parameters, molecular docking was performed, and the optimal binding conformation was selected to analyze the interaction. The Pymol software was used to visualize the results and generate a protein-ligand interaction diagram (see Figure 7 ).
[0076] The detailed results are shown in Table 1. The binding free energy of all ligand compounds with receptor proteins is less than -8 kcal / mol, indicating that all ligand compounds can bind to receptor proteins spontaneously and tightly. Among them, the binding free energy of compound 2-4 with FXR and SIRT1 is smaller than that of compound 1 (PGHG), indicating that compound 2-4 can form suitable spatial complementarity with FXR and SIRT1 and has a stronger interaction force.
[0077] The above results indicate that compounds 1-5 have the function of activating FXR and SIRT1, and play a protective role against cholestatic liver injury.
[0078] Table 1 Molecular docking results of compounds 1-5 with FXR and SIRT1
[0079]
[0080] Compounds 1-5 have the same configuration, with the 4- and 6-hydroxyl groups of glucose forming a ring with gallic acid, and are both able to bind to SIRT1 and FXR, indicating that compounds 1-5 can act as dual agonists of SIRT1 and FXR to treat cholestatic liver injury.
[0081] Animal experiments
[0082] Animal experiments were conducted using compound 1 as an example to verify the effects of compound 1 pyralidin-7-O-[3”-O-galloyl-4”,6”-hexahydroxybiphenyldicarboxylate]-β-D-glucoside (PGHG) on ALT, AST, ALP, TBIL and changes in liver pathological sections in mice with cholestasis caused by bile duct ligation (BDL).
[0083] 1. Experimental Animals
[0084] SPF male C57BL / 6 mice, weighing approximately 18–20 g, were purchased from Shanghai Jihui Experimental Animal Co., Ltd., China, with a certificate number of SCXK(Shanghai)2022-0009. They were housed in the barrier environment animal laboratory of Shanghai University of Traditional Chinese Medicine, with a room temperature of (22±1)°C, an indoor relative humidity of 65%±10%, and a 12-h light cycle. During the experiment, the animals had free access to food and water.
[0085] 2. Medication
[0086] pinocembrin-7-O-[3”-O-galloyl-4”,6”-(S)-hexahydroxydiphenoyl]-β-D-glucose (PGHG), homemade, purity higher than 95% by HPLC;
[0087] Ursodeoxycholic acid capsules (batch number L21384A, import sample registration certificate number: H20181059) were purchased from LosanPharma GmbH;
[0088] 3. Main reagents and instruments
[0089] Alanine aminotransferase (ALT) assay kit (Batch No. 20221018, Catalog No. S03030);
[0090] Aspartate aminotransferase (AST) assay kit (Batch No. 20220920, Catalog No. S03040);
[0091] Alkaline phosphatase (ALP) assay kit (Batch No. 20221027, Catalog No. S03038) was purchased from Redu Life Sciences Co., Ltd. |;
[0092] The total bilirubin (TBIL) assay kit (batch number 2022004, item number C120) was purchased from Changchun Huili Biotechnology Co., Ltd.;
[0093] Screen Master 3000 dual-channel semi-automatic biochemical analyzer: Hospitex;
[0094] Multifunctional microplate reader: Tecan;
[0095] 4. Experimental methods
[0096] Animal modeling: Use 11.5cm surgical scissors to cut the fascia from the midline of the abdominal cavity to open the abdomen, with a length of about 2cm. Use hemostats as dilators to expand the surgical area. Lift the liver with a cotton swab moistened with 0.9% NaCl solution so that its ventral side sticks to the diaphragm and the liver is clearly visible. Expose the bile duct by moving through the tail of the intestine. Use a glass needle to carefully separate the bile duct from the portal vein and hepatic artery on the side. Place a 4-0 suture around the bile duct and secure it with two surgical knots. Increase traction continuously when tying knots to ensure effective obstruction without cutting the bile duct. Cut off both ends of the suture, flush the abdominal cavity with 0.9% sodium chloride solution, and replace the abdominal organs to the physiological position. Use 6-0 sutures (round needles) to suture the peritoneum, fascia and skin respectively. Cut off both ends of the suture, disinfect the surgical area with a cotton swab dipped in iodine, and inject 20,000 units of penicillin.
[0097] Animal grouping: 42 SPF male C57BL / 6 mice weighing about 18-20g were selected and adaptively raised for 1 week to make them fully familiar with the environment. Then they were randomly divided into 5 groups as follows: normal group (Normal, group N, n = 6), model group (bile duct ligation, BDL, n = 10), low-dose PGHG group (L group, n = 10, 6 mg / kg*d), high-dose PGHG group (H group, n = 10, 54 mg / kg*d), ursodeoxycholic acid group (UCDA, group U, n = 6, 120 mg / kg*d). The drug was administered once every 24 hours, and the N group and BDL group were gavaged with the same volume of normal saline for a total of 14 days. On the 15th day, the mice in the remaining groups except the N group underwent common bile duct ligation surgery to create models, and continued to be administered for 7 days according to their respective doses.
[0098] Specimen preparation: 21 days after administration, mice in each group were fasted, whole blood was collected by eyeball blood sampling, stored in vacuum blood collection tubes, and centrifuged at 4000r / min for 10min after standing for two hours. The upper serum was collected and stored in a -80℃ refrigerator after aliquoting. Mouse liver tissue was collected, and 1cm long liver samples were taken, rinsed with saline, and immersed in fixative.
[0099] Index detection: According to the steps specified in the kit instructions, AST, ALT, ALP, TBA, TBIL, and DBIL in the serum of rats in each experimental group were measured to evaluate the degree of liver damage.
[0100] Liver histopathological examination:
[0101] (1) Dewaxing of paraffin sections: immerse the sections in xylene I for 20 minutes, xylene II for 20 minutes, anhydrous alcohol I for 5 minutes, anhydrous ethanol II for 5 minutes, and 75% alcohol for 5 minutes, and then wash with distilled water;
[0102] (2) Hematoxylin staining: The sections were stained with hematoxylin for 3-5 minutes, washed with distilled water, differentiated with differentiation solution, washed with distilled water, blued with bluing solution, and rinsed with running water;
[0103] (3) Eosin staining: The sections were immersed in 85% ethanol for 5 minutes, 95% ethanol for 5 minutes, and then eosin stained for 5 minutes;
[0104] (4) Dehydration and sealing: immerse in anhydrous ethanol I for 5 minutes, immerse in anhydrous ethanol II for 5 minutes, immerse in anhydrous ethanol III for 5 minutes, immerse in xylene I for 5 minutes, and immerse in xylene II for 5 minutes. Seal the slides with neutral gum and observe under a microscope.
[0105] Western blot examination of liver tissue:
[0106] (1) Protein quantification: Prepare protein standard solution and protein sample to be tested, incubate at 37°C in the dark for 30 min, measure absorbance at 562 nm with an ELISA reader, and calculate protein concentration.
[0107] (2) SDS-PAGE electrophoresis: Fix the successfully prepared PAGE gel in the electrophoresis tank, add an appropriate amount of electrophoresis buffer, load the protein to be tested and the standard protein marker in turn, connect the power supply, set the electrophoresis program, 80V for 30min for the concentrating gel and 120V for the separating gel, and set the time according to the size of the target protein until the target protein is completely separated.
[0108] (3) Transfer: Transfer the proteins on the gel after electrophoresis to the PVDF membrane by transfer electrophoresis.
[0109] (4) Blocking, primary antibody incubation, and secondary antibody incubation: The transferred PVDF membrane was blocked with 5% skim milk powder at room temperature for 2 h with slow shaking, washed once with 1× TBST, incubated with primary antibody at 4°C overnight, washed three times with 1× TBST, and incubated with secondary antibody at room temperature for 1 h.
[0110] (5) Development: Take out the target band membrane, wash it with absorbent paper, immerse it in enhanced chemiluminescence reagent solution for 1 minute, and develop it in a chemiluminescence imaging system.
[0111] 6. Statistical analysis
[0112] GraphPad Prism (GraphPad Software, Inc., USA) was used for data analysis. The measured values were expressed as mean ± standard deviation. OneWayANOVA was used for data with equal variance among multiple groups, and WelchANOVA was used for data with unequal variance. p < 0.05 was considered statistically significant.
[0113] Experimental Results
[0114] (1) Observation of general condition of mice
[0115] During the construction of the BDL-induced cholestatic liver injury mouse model, the mice in group N had normal hair and paw color, normal mental state, and normal diet; the mice in group BDL had dull hair color with a yellowing trend, listlessness, and yellow changes in the limbs; after drug intervention, the weight of mice in groups L and H had improved hair color, mental state, and yellow changes in the limbs compared with the BDL group.
[0116] (2) Effects of PGHG on serum biochemical parameters in mice with cholestasis caused by bile duct ligation
[0117] See also Figure 1 , Figure 2 The results of liver function biochemical experiments showed that the levels of ALT and AST in the serum of mice with cholestasis caused by bile duct ligation were significantly higher than those in the normal group (P < 0.05), indicating that cholestasis caused by bile duct ligation caused liver damage. Continuous administration of PGHG high- and low-dose groups and UDCA for 21 days reduced the levels of ALT and AST in the serum of mice with cholestasis caused by bile duct ligation, among which low-dose PGHG could significantly reduce the level of AST in mouse serum (P < 0.05). The above results show that PGHG has a protective effect on liver damage in mice with cholestasis caused by bile duct ligation, and the effect is better than the protective effect of UCDA.
[0118] See also Figure 3 , Figure 4The results of changes in serum ALP and TBIL levels showed that the serum ALP and TBIL levels of mice with cholestasis caused by bile duct ligation were significantly increased compared with those of the normal group (P < 0.05). Continuous administration of PGHG high and low dose groups for 21 days had a reducing effect on the serum ALP and TBIL levels of mice with cholestasis caused by bile duct ligation, among which the high and low doses of PGHG could significantly reduce the level of TBIL in the serum of mice (P < 0.05), while UCDA could not reduce the levels of ALP and DBIL in the serum of mice with cholestasis caused by bile duct ligation.
[0119] (3) Effects of PGHG on liver pathological sections of mice with cholestasis caused by bile duct ligation
[0120] HE staining results Figure 5 The results showed that the hepatocytes in group N were arranged neatly, the nuclei were clearly shaped, the hepatic sinusoids between the hepatocytes were obvious, there was no inflammatory cell infiltration, and no obvious pathological damage; the hepatocytes in group BDL were arranged disorderly, the hepatocytes were swollen and degenerated, severe focal necrosis appeared around the portal area, and there were a large number of inflammatory cell infiltration areas; some hepatocytes in group L were arranged disorderly, there was focal necrosis locally, and the inflammatory cell infiltration was reduced; the hepatocyte structure in group H was relatively complete, the hepatic lobule structure was relatively clear, and there was mild inflammatory infiltration; some hepatocytes in group U were arranged disorderly, the inflammatory cell infiltration was reduced compared with the BDL group, and there were still several focal necrosis areas. The above results show that PGHG administration can alleviate liver damage caused by BDL.
[0121] (4) Effects of PGHG on SIRT1 and FXR in the liver of mice with cholestasis caused by bile duct ligation
[0122] Western blot results Figure 6 The results showed that the relative expression of FXR in the BDL group was lower than that in the N group, and the expression of FXR was increased in the U, L and H groups compared with the BDL group; the relative expression of SIRT1 in the BDL group was lower than that in the N group, and there was an upward trend in the L, H and U groups compared with the BDL group. The above results indicate that PGHG can activate the expression of SIRT1 and FXR in the liver of mice with cholestasis caused by bile duct ligation.
[0123] In summary, compound 1, pyralidin-7-O-[3”-O-galloyl-4”,6”-hexahydroxybiphenyldicarboxylate]-β-D-glucoside (PGHG), can reduce the levels of ALT, AST and ALP in liver tissue of cholestatic liver loss, and can promote the expression of SIRT1 and FXR in the liver, and has the potential to be developed as a dual agonist of SIRT1 and FXR.
[0124] Compounds 2-5 have the same configuration. The above molecular docking experiments show that compounds 1-5 all have the function of activating FXR and SIRT1, and can also act as dual agonists of SIRT1 and FXR to treat cholestatic liver injury.
[0125] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A macrocyclic polyphenol compound, characterized in that Includes at least one of the following chemical formulas:
2. The method for preparing a macrocyclic polyphenol compound according to claim 1, characterized in that: The compound 2 is prepared by the following method: The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract; The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4; Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4; Fr.4.4 was used as a sample and wet loading was performed for ODS column chromatography. Compound 2 was obtained after purification by semi-preparative liquid chromatography.
3. The method for preparing a macrocyclic polyphenol compound according to claim 1, characterized in that: The compound 3 was prepared by the following method: The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract; The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4; Fr.3 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.3.1 to Fr.3.3; Fr.3.3 was used as a sample and wet loading was performed for ODS column chromatography. Compound 3 was obtained after purification by semi-preparative liquid chromatography.
4. The method for preparing a macrocyclic polyphenol compound according to claim 1, characterized in that: The compound 4 was prepared by the following method: The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract; The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4; Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4; Fr.4.2 was used as a sample and wet loading was performed for ODS column chromatography. Compound 4 was obtained after purification by semi-preparative liquid chromatography.
5. The method for preparing a macrocyclic polyphenol compound according to claim 1, characterized in that: The compound 5 was prepared by the following method: The ethanol extract of the herb was concentrated, and then subjected to gradient elution by macroporous resin column chromatography, eluted with ethanol of different concentrations in turn, the eluate was collected, and concentrated under reduced pressure to obtain a 50% ethanol extract; The extract was isocratically eluted with methanol-swollen dextran gel to obtain fractions Fr.1 to Fr.4; Fr.4 was used as sample and dry loading was adopted to perform ODS reverse phase column chromatography to obtain fractions Fr.4.1 to Fr.4.4; Fr.4.3 was used as a sample and wet loading was performed on an ODS column chromatography (30% acetonitrile as the mobile phase). Compound 5 was obtained after purification by semi-preparative liquid chromatography.
6. The method for preparing a macrocyclic polyphenol compound according to any one of claims 2 to 5, characterized in that: The concentrated ethanol extract of the herb was subjected to gradient elution at least twice by macroporous resin column chromatography, with a diameter-to-height ratio of 1:4, 1 BV = 1.3 L, and eluted with 9 to 11 BV of 25% ethanol, 50% ethanol, and 95% ethanol in sequence, and the eluate was collected and concentrated under reduced pressure to obtain a 50% ethanol extract, and the 50% ethanol extract was isocratically eluted by methanol-swollen polysaccharide gel LH-20; and / or, using Fr.3.3 as sample and wet loading, and performing ODS column chromatography with 30% acetonitrile as the mobile phase; and / or, using Fr.4 as sample and dry loading, and performing ODS reverse phase column chromatography with 35% acetonitrile as mobile phase; and / or, using Fr.4.2 as sample and wet loading, and using 33% acetonitrile as mobile phase for ODS column chromatography; and / or, using Fr.4.3 as sample and wet loading, and using 30% acetonitrile as mobile phase for ODS column chromatography; And / or, using Fr.4.4 as sample and adopting wet loading method, when performing ODS column chromatography, use 20% acetonitrile as mobile phase.
7. Use of a macrocyclic polyphenol compound in the preparation of a drug for cholestatic liver injury, characterized in that: The macrocyclic polyphenol compound is at least one of the compounds of the following structural formulas:
8. Use of a macrocyclic polyphenol compound according to claim 7 in the preparation of a drug for cholestatic liver injury, characterized in that: The medicine is a medicine composition consisting of a macrocyclic polyphenol compound as an active ingredient and pharmaceutical excipients.
9. Use of a macrocyclic polyphenol compound according to claim 8 in the preparation of a drug for cholestatic liver injury, characterized in that: The pharmaceutical composition includes tablets, capsules, granules, powders or pills.
Citation Information
Patent Citations
An extract of Penthorum chinense Pursh, its preparation method and uses
CN105125601B
Use of a monomer of Penthorum chinense Pursh in the preparation of a liver protection drug
CN105193833B
Penthorum chinense pursh extractive and application thereof
CN108478610A
